Skip to main content
SpringerLink
Log in

Antibody-Drug Conjugates

  • Book
  • © 2013

Overview

Editors:
  1. Laurent Ducry

    1. Lonza Ltd, Visp, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Supports the development of innovative cancer treatments through ADC techniques
  • Provides step-by-step methodologies that are readily reproducible
  • Features expert tips and key implementation advice to ensure successful results
  • Includes supplementary material: sn.pub/extras

Part of the book series: Methods in Molecular Biology (MIMB, volume 1045)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (20 protocols)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review

    • Ingrid Sassoon, Véronique Blanc
    Pages 1-27

  3. Antibody–Drug Conjugate Target Selection: Critical Factors

    • Neil H. Bander
    Pages 29-40

  4. Selecting an Optimal Antibody for Antibody–Drug Conjugate Therapy: Internalization and Intracellular Localization

    • Jay Harper, Shenlan Mao, Patrick Strout, Adeela Kamal
    Pages 41-49

  5. Antibody–Drug Conjugate Payloads

    • Jan Anderl, Heinz Faulstich, Torsten Hechler, Michael Kulke
    Pages 51-70

  6. Linker Technologies for Antibody–Drug Conjugates

    • Birte Nolting
    Pages 71-100

  7. In Vivo Testing of Drug-Linker Stability

    • Pierre-Yves Abecassis, Céline Amara
    Pages 101-116

  8. Pharmacokinetics and ADME Characterizations of Antibody–Drug Conjugates

    • Kedan Lin, Jay Tibbitts, Ben-Quan Shen
    Pages 117-131

  9. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment

    • Miriam I. Hensgen, Bernhard Stump
    Pages 133-143

  10. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting

    • James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, Diego A. Gianolio
    Pages 145-171

  11. Protocols for Lysine Conjugation

    • Marie-Priscille Brun, Laurence Gauzy-Lazo
    Pages 173-187

  12. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers

    • Sunil Bhakta, Helga Raab, Jagath R. Junutula
    Pages 189-203

  13. Enzymatic Antibody Modification by Bacterial Transglutaminase

    • Patrick Dennler, Roger Schibli, Eliane Fischer
    Pages 205-215

  14. Formulation Development of Antibody–Drug Conjugates

    • William J. Galush, Aditya A. Wakankar
    Pages 217-233

  15. Conjugation Process Development and Scale-Up

    • Bernhard Stump, Jessica Steinmann
    Pages 235-248

  16. Methods for Conjugating Antibodies to Nanocarriers

    • Anil Wagh, Benedict Law
    Pages 249-266

  17. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy

    • Yan Chen
    Pages 267-273

  18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High-Performance Liquid Chromatography

    • Jun Ouyang
    Pages 275-283

  19. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS

    • Louisette Basa
    Pages 285-293

  20. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF

    • Joyce Lin, Alexandru C. Lazar
    Pages 295-302
Back to top

Keywords

About this book

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs.  In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion.  Written in the highly successful Methods in Molecular Biology™ format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.

 

Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.

Editors and Affiliations

  • Lonza Ltd, Visp, Switzerland

    Laurent Ducry

Bibliographic Information

  • Book Title: Antibody-Drug Conjugates

  • Editors: Laurent Ducry

  • Series Title: Methods in Molecular Biology

  • DOI: https://doi.org/10.1007/978-1-62703-541-5

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Protocols

  • Copyright Information: Springer Science+Business Media, LLC 2013

  • Hardcover ISBN: 978-1-62703-540-8Published: 03 August 2013

  • Softcover ISBN: 978-1-4939-6026-2Published: 23 August 2016

  • eBook ISBN: 978-1-62703-541-5Published: 04 August 2013

  • Series ISSN: 1064-3745

  • Series E-ISSN: 1940-6029

  • Edition Number: 1

  • Number of Pages: X, 317

  • Number of Illustrations: 54 b/w illustrations, 42 illustrations in colour

  • Topics: Pharmacology/Toxicology, Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation